Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.57 |
| ▸ | CDK8 | P49336 | 7/20 | 0.38 |
| ▸ | CCNC | P24863 | 6/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22172615 | 1.00 | OTUD7B (0.57) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL20414626 | 1.00 | OTUD7B (0.57) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL24859554 | 0.89 | OTUD7B (0.50) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL14377176 | 0.89 | OTUD7B (0.50) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL5559483 | 0.88 | OTUD7B (0.51) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL23260107 | 0.86 | OTUD7B (0.49) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL16562302 | 0.82 | OTUD7B (0.39) | OTUD7BCHRM2CHRM3NEK2 | |
| SCHEMBL16750994 | 0.81 | OTUD7B (0.42) | OTUD7BCDK8CCNCCDK19GRIN1 | |
| SCHEMBL2605421 | 0.77 | OTUD7B (0.41) | OTUD7BCDK8CCNCJAK1TYK2 | |
| SCHEMBL24718639 | 0.77 | OTUD7B (0.53) | OTUD7BCDK8CCNCJAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| EP-3344624-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| WO-2019111218-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2019-06-13 | — | — | WO | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | OTUD7B 1335/4885CDK8 395/4885CCNC 3303/4885 |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | OTUD7B 1482/4885CDK8 614/4885CCNC 33/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | OTUD7B 2098/4885CDK8 301/4885CCNC 324/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | OTUD7B 2098/4885CDK8 301/4885CCNC 324/4885 |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | OTUD7B 1643/4885CDK8 434/4885CCNC 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.